Superworth

Protalix BioTherapeutics price to free cash flow PLX

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Nov 2, 2026
26.9×
8-year median
18.5×
Against its 8-year history
82nd
percentile: 0 is its lowest day, 100 its highest
8-year range
3.3× to 31.7×
Peer median
12.0×

Protalix BioTherapeutics' price to free cash flow is 26.9× as of Nov 2, 2026.

That is above its 8-year median of 18.5×, higher than on 82% of days in the last 8 years.

Over that time it ranged from 3.3× in Dec 2018 to 31.7× in May 2025.

The median for 10 healthcare stocks of a similar size is 12.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far26.9×12.3×29.2×
202531.7×21.8×31.7×
202418.8×14.4×20.6×
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
20195.6×4.3×6.2×
20183.3×3.3×5.1×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

CompanyPrice to free cash flow
PLXProtalix BioTherapeutics26.9×
NATRNatures Sunshine Products11.7×
ELMDElectromed26.6×
UTMDUtah Medical Products19.6×
PDEXPro DEX17.3×
INFUInfuSystem12.0×
CYHCommunity Health Systemsn/m
EMBCEmbecta2.1×
VMDViemed Healthcare12.3×
CRMDCorMedix1.7×
KEQUKewaunee Scientific8.9×
Peer median12.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.